HIV Therapy Glasgow 2020

Introduction

Simon Collins, HIV i-Base

This year, the biennial Glasgow HIV Congress was held from 5-8 October as a virtual meeting.

The conference website is easy to navigate, with most oral presentations already prerecorded but with presenters also being online for Q&A discussions afterwards.

The programme this year is particularly strong, with a focus on COVID-19 and how it affects people living with HIV and our care, and on important concerns about women’s health and weight gain experienced by some people as a side effect of ART. As always, there are also exciting studies on next generation treatment.

For registered delegates, webcasts are being posted on the same day of the oral presentation and the meeting will be open access to everyone when the meeting closes.

https://virtual.hivglasgow.org

Reports from the meeting in this issue of HTB with be linked below as they become available.

• Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg
• Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes
• COVID-19: pathogenesis and treatment
• EACS guidelines updated (v.10.1) for Glasgow conference

This report was first published online on 5 October 2020.